In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
In two weeks' time, independent mutual fund directors will gather in New York to discuss issues related board composition and diversity in the boardroom. The directors—and ...
Investment Company Institute CEO Eric Pan came out swinging on Tuesday, delivering keynote remarks to 2024 Investment Management Conference attendees in which he railed against "over-regulation" and vowed ...
A senior member of the Securities and Exchange Commission's Division of Investment Management on Monday indicated to mutual fund industry professionals that the Commission will not ...
Today is International Women's Day, and there's plenty to celebrate in the mutual fund governance space. Women have made strides in recent years in getting into ...